RAB39B

Across TCGA pan-cancer cohorts, RAB39B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB39B data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RAB39B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAB39B expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and GBM are the cancer types where RAB39B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.847	0.189	.006	13	view →
LUAD	OS	Median	All	0.379	0.886	.007	11	view →
GBM	DFS	Median	All	0.839	0.660	.008	5	view →
LSCC	DFS	Median	All	0.876	1.000	.008	4	view →
HNSC	OS	Median	All	0.904	0.554	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB39B–PDAC (DFS)

Open the PDAC breakdown →